REFERENCES

- 1. J. P. Johnston, Biochem. Pharmac. 17, 1285 (1968).
- 2. R. McCauley and E. Racker, Molec. cell. Biochem. 1, 73 (1973).
- 3. H.-Y. T. Yang and N. H. Neff, J. Pharmac. exp. Ther. 187, 365 (1973).
- J. A. Roth and C. N. Gillis, J. Pharmac. exp. Ther. 194, 537 (1975).
- 5. N. H. Neff and H-Y. T. Yang, Life Sci. 14, 2061 (1974).
- 6. J. A. Roth, Gen. Pharmac. 7, 381 (1976).
- M. D. Houslay and K. F. Tipton, *Biochem. J.* 139, 645 (1974).
- 8. H.-Y. T. Yang and N. H. Neff, J. Pharmac. exp. Ther. 189, 733 (1974).
- C. Braestrup, H. Anderson and A. Randrup, Eur. J. Pharmac. 34, 181 (1975).
- P. C. Waldmeier, A. D. Stula and L. Maitre, Naunyn-Schmiedebergs Arch. Pharmac. 292, 9 (1976).
- V. Glover, M. Sandler, F. Owen and G. J. Riley, Nature, Lond. 265, 80 (1977).

- K. F. Tipton, M. D. Houslay and N. J. Garrett, *Nature*, *New Biol.* 246, 213 (1973).
- 13. H. Y. Meltzer and S. M. Stahl, Schizophrenia Bull. 2, 19 (1976).
- E. D. Bird and L. L. Iverson, in Essays in Neurochemistry and Neuropharmacology (Eds. M. B. H. Youdim, W. Lovenberg, D. F. Sharman and J. R. Langnado), Vol. 1, pp. 177-95. Wiley-Interscience, New York (1977).
- 15. J. A. Roth, J. Neurochem. 27, 1107 (1976).
- J. A. Roth, X. O. Breakefield and C. M. Castiglione, Life Sci. 19, 1705 (1976).
- 17. H. L. White and J. C. Wu, J. Neurochem. 25, 21 (1975).
- D. J. Edwards and S. S. Chang, Biochem. biophys. Res. Commun. 65, 1018 (1975).
- H. L. White and A. T. Glassman, J. Neurochem. 29, 987 (1977).
- D. S. Robinson, T. L. Sourkes, A. Nies, L. Harris, S. Spector, D. L. Bartlett and I. S. Kaye, Archs gen. Psychiat. 34, 89 (1977).

Biochemical Pharmacology, Vol. 27, pp. 1608–1609. © Pergamon Press Ltd. 1978. Printed in Great Britain. 0006-2952/78/0601-1608/\$02.00/0

Metabolism in vivo of carbon disulfide to carbonyl sulfide and carbon dioxide in the rat

(Received 9 July 1977; accepted 19 October 1977)

Carbon disulfide (CS₂) is metabolized to carbonyl sulfide (COS) by rat hepatic microsomes [1]. The reaction requires NADPH, is inhibited by carbon monoxide, and is stimulated by pretreatment of the rats with phenobarbital. Thus, it appears that the metabolism *in vitro* of CS₂ to COS is catalyzed by the cytochrome P-450 containing monoxygenase systems. Additional studies have indicated that COS is metabolized *in vitro* to CO₂, again in a reaction catalyzed by the rat hepatic cytochrome P-450 containing mono-oxygenase system [2]. Studies by DeMatteis and Seawright [3] have shown that [14C]CS₂ is metabolized *in vivo* in rats to [14C]CO₂. The purpose of the present studies was to determine if [14C]CS₂, administered *in vivo* to rats, was also excreted in the breath as [14C]COS.

In these experiments, untreated or phenobarbital-pretreated male Sprague-Dawley rats (250-275 g) were given [¹⁴C]CS₂ dissolved in corn oil by i.p. injection and placed individually in a 3-l. metabolic apparatus. The phenobarbital-pretreated rats received i.p. injections of 50 mg/kg of sodium phenobarbital in distilled water for 5 days followed by administration of the [¹⁴C]CS₂ 24 hr after the last injection. The expired air was drawn through a trap containing 200 ml of 1 N NaOH and, in turn, through two traps, each containing 35 ml of a 95% ethanol-diethylamine mixture (1:1, v/v). The airflow through the system was

approximately 1.5 l./min. Three doses of [14 C]CS $_2$ were given; these were 0.0625, 0.125 and 0.250 m-mole/kg, representing 5.64, 11.28 and 22.55 μ Ci/kg respectively. There were three animals at each dose. The expired air was collected for 4 hr. Preliminary experiments indicated that expiration of radioactivity after administration of [14 C]CS $_2$ was essentially complete in 3 hr. DeMatteis and Seawright [3] reported that the exhalation of intraperitoneally administered [14 C]CS $_2$ was virtually complete in 4 hr.

Experiments in which [14C]CS₂ was introduced into the metabolic apparatus indicated that only a trace of the [14C]CS₂ was retained in the first trap (1 N NaOH). The majority was retained in the second trap (95% ethanoldiethylamine, 1:1, v/v) with a small amount appearing in the third trap, which contained the same solution as the second. Similar experiments using [14C]COS showed that about 28 per cent was retained by the first trap and the remainder was found in the second trap. No attempt was made to determine the distribution of [14C]CO₂ among the various traps. However, the NaOH trap worked very efficiently for CO₂, and the possibility of spillover of [14C]CO₂ into the second and third traps appeared remote. [14C]CO₂ formation after administration *in vivo* of [14C]CS₂ was determined by liquid scintillation counting of

Table 1. [14C]CO2 and COS content of expired air of untreated rats administered [14C]CS2*

| Dose [14C]CS ₂ (m-mole/kg) | Amount [14C]CS ₂ administered (µmoles) | Amount [14C]CO ₂ excreted (μmoles) | Amount [14C]COS excreted (µmoles) | Amount [14C]CS ₂ excreted (µmoles) | Total recovery of administered dose (%) |
|---|--|--|-----------------------------------|---|---|
| 0.0625 | 16.54 ± 0.93 | 1.82 ± 0.06 | 4.20 ± 0.19 | 4.94 ± 0.79 | 66.8 ± 11.2 |
| 0.125 | 32.52 ± 3.24 | 2.23 ± 0.08 | 4.32 ± 0.38 | 12.59 ± 1.78 | 59.5 ± 11.4 |
| 0.250 | 60.57 ± 4.86 | 4.06 ± 0.25 | 4.48 ± 0.20 | 43.99 ± 6.89 | 86.5 ± 4.42 |

^{*} Each value is the mean \pm S.D. of the data obtained from three rats.

Table 2. [14C]CO2 and COS content of expired air of phenobarbital-pretreated rats administered [14C]CS2*

| Dose [14C]CS ₂ (m-mole/kg) | Amount [14C]CS ₂ administered (µmoles) | Amount [14C]CO ₂ excreted (µmoles) | Amount [14C]COS excreted (µmoles) | Amount ¹⁴ C CS ₂ excreted (μmoles) | Total recovery of administered dose (%) |
|---|---|---|---|---|---|
| 0.0625 0.125 0.250 | 15.66 ± 1.05 32.98 ± 2.59 69.58 ± 3.92 | 4.27 ± 0.63 8.01 ± 1.16 9.71 ± 1.97 | 2.69 ± 0.84 4.39 ± 0.63 5.23 ± 0.40 | $ 1.11 \pm 0.98 6.93 \pm 0.53 20.32 \pm 3.88 $ | 48.6 ± 11.0 58.9 ± 7.9 51.0 ± 9.0 |

^{*} Each value is the mean \pm S.D. of the data obtained from three rats.

an aliquot from the first trap; this was corrected for the amount of COS present. COS was determined by gas chromatography [1] using essentially the method described by Thornsberry [4]. CS₂ concentrations in the second and third traps were determined colorimetrically [5].

[14C]CS₂ (58 mCi/m-mole) was a product of the Amersham-Searle Corp. The purity was greater than 99 per cent, determined by gas chromatography [4]. [14C]COS was synthesized as described previously [2].

Table 1 shows the results of analyses of expired air of untreated rats given [14C]CS₂. The recovery of the administered dose as [14C]CO₂ ranged from 7 per cent at 0.25 m-mole to 11 per cent at 0.0625 m-mole/kg. [14C]COS accounted for 7 per cent of the administered dose at 0.25 m-mole/kg. 13 per cent at 0.125 m-mole/kg, and 25 per cent at 0.0625 m-mole/kg. Recovery of administered radioactivity as unchanged CS₂ ranged from 30 per cent at 0.0625 m-mole/kg to 72 per cent at 0.25 m-mole/kg. Total recovery of administered radioactivity in expired air is shown in the last column of Table 1.

Table 2 lists the amounts of the various doses of [14C]CS2 administered to phenobarbital-pretreated rats which were excreted in the breath as [14C]CO2 and [14C]COS. In untreated rats, the predominant metabolite was COS. In the phenobarbital-pretreated animals, CO2 was more important, ranging from 14 per cent of the administered dose at 0.25 m-mole/kg to 27 per cent at 0.0625 m-mole/kg. The COS was 8 per cent of the administered dose at 0.25 m-mole/kg, 13 per cent at 0.125 m-mole/kg, and 17 per cent at 0.0625 m-mole/kg. The increased metabolism of CS2 to COS and CO, in the phenobarbital-pretreated rats is reflected in a decreased recovery of the administered dose as unchanged CS2. An increased metabolism of CS2 to CO2 in phenobarbital-pretreated rats has been noted previously [3]. Also, as noted previously [3], there is a decreased total recovery of the administered dose of [14C]CS2 in phenobarbital-treated rats as compared to untreated rats. The reason for this decreased recovery is not known.

From these experiments it is clear that CS2 is metabo-

lized to COS in vivo. In untreated rats it is the predominant metabolite excreted in the expired air. After treatment with phenobarbital, more of the administered CS₂ is metabolized to COS and CO₂, with CO₂ being the predominant metabolite. This increased rate of metabolism in vivo of CS₂ in phenobarbital-pretreated rats is in agreement with in vitro data showing an increased rate of metabolism of CS₂ to COS using microsomes from phenobarbital-pretreated rats [1]. The in vitro data [1, 2] indicate that the metabolism of CS₂ to CO₂ involves, first, the cytochrome P-450 mono-oxygenase-catalyzed metabolism of CS₂ to COS, followed by metabolism of COS to CO₂ by these same enzyme systems. The present experiments suggest that the same sequence of reactions is operative in vivo.

Acknowledgement—This work was supported by National Institutes of Health Grants ES 00267 and ES 00075.

RAMESH R. DALVI

Department of Physiology and Pharmacology,

School of Veterinary Medicine,

Tuskegee Institute,

Tuskegee, AL 36088, U.S.A.

Center in Environmental Toxicology, ROBERT A. NEAL Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, U.S.A.

REFERENCES

- R. R. Dalvi, R. E. Poore and R. A. Neal, Life Sci. 14, 1785 (1974).
- R. R. Dalvi, A. L. Hunter and R. A. Neal, Chem. Biol. Interact. 10, 347 (1975).
- 3. F. DeMatteis and A. A. Seawright, Chem. Biol. Interact. 7, 375 (1973).
- 4. W. L. Thornsberry, Jr., Analyt. Chem. 43, 452 (1971).
- 5. R. W. McKee, J. ind. Hyg. Toxicol. 23, 151 (1941).